Editor's PickMarket News

Revive Therapeutics updates further on its Phase 3 Bucillamine in coronavirus trial

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has updated on its Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19), saying it is still targeting the second quarter this year to meet its patient enrollment goals. “With COVID-19 cases on the rise and the need for alternative oral treatments that is relevant to the current state of the disease, we believe that Bucillamine’s anti-inflammatory and antiviral properties offers an alternative potential solution that is urgently needed globally to fight COVID-19 and allow for people to improve their quality of life,” Michael Frank, CEO of Revive said in a statement. The company noted that the data safety and monitoring board (DSMB) was scheduled to meet this quarter to evaluate current clinical and safety data, either making recommendations on the study or advising on potentially halting it early “due to positive efficacy based on other clinical outcomes evaluated such as the rate of sustained clinical resolution of symptoms of COVID-19”. READ: Revive Therapeutics to seek data safety board nod for emergency use application to FDA for Bucillamine in COVID-19 in 2Q “The company has made efforts in determining the appropriate revised primary and secondary clinical endpoints for FDA consideration for potential Emergency Use Authorization. In parallel, the company will continue enrollment activities in the U.S. and Turkey and is still targeting Q2-2022 to meet the enrollment goals,” Revive said. The clinical study is aimed at evaluating the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Revive Therapeutics is focused on the research and development of therapeutics for infectious diseases and rare disorders, and aims to take advantage of several regulatory incentives awarded by the US Food & Drug Administration (FDA) such as orphan drug, fast track, breakthrough therapy and rare pediatric disease designations. Contact the writer at giles@proactiveinvestors.com